Asthma Inhalers in India: Classes, Evidence & Stocking
A clinical-reference overview of asthma inhaler classes used in India, GINA 2024 treatment tracks, NLEM listing and hospital pharmacy stocking reality.
This piece covers the inhaler classes used in Indian practice, what GINA 2024 changed, where these devices sit on the National List of Essential Medicines, and why in-house stocking of the right asthma inhaler India patients are already stabilised on matters more here than for most chronic conditions.
What are the main classes of asthma inhalers used in India?
Indian prescribing follows four broad device-and-molecule classes. SABAs (salbutamol, levosalbutamol) give quick relief. ICS monotherapy (budesonide, fluticasone, beclomethasone) provides maintenance anti-inflammatory control. ICS-LABA combination inhalers (budesonide-formoterol, fluticasone-salmeterol) cover step-up maintenance and reliever use. Add-on long-acting muscarinic antagonists such as tiotropium serve more severe or overlap disease, per the 2024 GINA report cited below.
Metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are both in routine use; nebulised respules of salbutamol and budesonide remain common in Indian emergency departments and paediatric wards. Device choice affects deposition and technique training as much as the drug itself, which is why a hospital pharmacy stocking the wrong device format for a patient population is a real clinical gap, not a minor inconvenience.
What changed in the GINA 2024 treatment strategy?
The 2024 GINA Global Strategy for Asthma Management and Prevention restructured treatment into two tracks: Track 1, the preferred track, uses as-needed low-dose ICS-formoterol as the reliever at every step, including in patients previously managed on SABA alone. Track 2 retains a separate SABA reliever alongside a controller ICS inhaler for patients already stable on that regimen.
The strategy's central change is dropping SABA-only reliever therapy as an acceptable default for adults and adolescents, based on evidence that SABA-only use is associated with higher exacerbation and mortality risk than ICS-containing regimens. This is a strategy document, not a prescribing script for a specific patient, and Indian prescribers adapt track selection to device availability and patient affordability locally.
How large is India's asthma burden, and why does mortality run high?
Community studies put asthma prevalence in India in the roughly 3.3–8.7% range depending on region and diagnostic method, and India was estimated to contribute around 13% of the global asthma case burden while accounting for a disproportionately higher share, around 43%, of global asthma deaths. Under-diagnosis, late presentation, inconsistent inhaler technique and inconsistent access to controller medication are the most frequently cited drivers in the Indian respiratory literature.
A 2024 call-to-action published in Lung India, the journal of the Indian Chest Society, specifically flagged gaps in asthma diagnosis infrastructure and treatment access as a persistent national problem, distinct from the disease's clinical severity itself. That distinction matters for a hospital administrator: mortality here tracks system gaps at least as much as pharmacology.
Where do asthma inhalers sit in India's essential medicines and pricing framework?
Salbutamol and beclomethasone/budesonide-class respiratory medicines are listed in India's National List of Essential Medicines (NLEM) 2022, which the Ministry of Health and Family Welfare maintains jointly with CDSCO and which the National Pharmaceutical Pricing Authority (NPPA) uses to set ceiling prices for scheduled formulations under the Drugs (Prices Control) Order.
Listing on the NLEM does not fix every dosage-and-device combination at one uniform ceiling price; NPPA revises ceiling prices for scheduled formulations annually based on the Wholesale Price Index, and combination ICS-LABA devices in particular vary meaningfully in retail price across brands even where the underlying molecules are chemically equivalent. A hospital or clinic procuring inhalers should check the current NLEM 2022 schedule and NPPA notification directly rather than relying on a remembered price point, since both are revised on a fixed annual cycle.
What interactions and precautions matter clinically with these inhaler classes?
Beta-agonist inhalers can potentiate the hypokalaemic effect of loop and thiazide diuretics. They also interact with non-selective beta-blockers, which blunt bronchodilator response and are generally avoided in reactive airway disease. High cumulative ICS exposure across two or more inhaler sources raises the same systemic corticosteroid concern as any other chronic steroid route.
Tiotropium and other muscarinic antagonists carry anticholinergic considerations relevant to patients with narrow-angle glaucoma or significant prostatic obstruction, which is a standard part of the add-on decision rather than a contraindication in the general asthma population. None of this substitutes for an individual prescribing decision; it is the class-level interaction landscape a hospital pharmacist should already be trained to flag at dispensing.
Does inhaler device type affect how reliably a hospital pharmacy can stock it?
Yes, and this is where the Indian hospital pharmacy picture gets genuinely difficult. MDIs, DPIs and nebuliser respules are three distinct SKUs per molecule, often across three or four brand manufacturers, which multiplies the stock-keeping burden for what a prescriber experiences as "one inhaler."
A ward that stabilises a patient on a specific device-brand combination during admission, only for the discharge prescription to be unavailable in the hospital's own pharmacy, routinely sends that prescription to an outside chemist — and outside substitution on an inhaler is not a like-for-like swap the way a tablet substitution often is, because technique, dose-counter design and spacer compatibility differ by device. Our prescription leakage guide covers what this kind of walk-out costs a hospital in both continuity of care and lost pharmacy revenue, and our managed hospital pharmacy services piece covers how a properly stocked in-house or managed pharmacy closes that specific gap for chronic respiratory patients who need the same device, refill after refill.
Sources
- 12024 GINA Global Strategy for Asthma Management and Prevention — Global Initiative for Asthma
- 2Call to action: Addressing asthma diagnosis and treatment gaps in India — Lung India, Indian Chest Society, 2024
- 3Patterns, factors associated and morbidity burden of asthma in India — National Institutes of Health, National Library of Medicine
- 4National List of Essential Medicines (NLEM) 2022 — CDSCO / Ministry of Health and Family Welfare
- 5National List of Essential Medicines, 2022 — National Pharmaceutical Pricing Authority
- 6Chronic obstructive pulmonary disease and asthma — World Health Organization
- 7Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
This article is for informational purposes and is for hospital and clinical administrators, not patients seeking self-treatment advice. It is not a substitute for professional medical advice; drug classes, interactions and pricing details cited here change over time and should be verified against current primary sources. Consult a qualified physician before making any treatment decision.
FAQ
Frequently asked questions
A SABA (salbutamol, levosalbutamol) is a fast-acting reliever for immediate symptom relief with no anti-inflammatory effect. An ICS-LABA combination inhaler pairs an anti-inflammatory steroid with a long-acting bronchodilator and is used for ongoing maintenance control, and under GINA 2024's Track 1, a low-dose ICS-formoterol combination can also serve as the reliever itself.
Salbutamol and several ICS-class respiratory molecules are listed on the NLEM 2022 and subject to NPPA ceiling pricing under the Drugs (Prices Control) Order, though ceiling prices are revised annually and vary by specific formulation and pack size, so a current NPPA notification should be checked rather than a remembered figure.
Published Indian respiratory literature attributes this gap primarily to under-diagnosis, inconsistent access to controller inhalers, and gaps in inhaler-technique training, rather than to the underlying disease being clinically more severe in Indian patients than elsewhere.
Chemically, yes — nebulised salbutamol and budesonide respules deliver the same molecule as their MDI or DPI counterparts, but the delivery device, deposition pattern and typical clinical setting (nebulisers are common in emergency and paediatric wards) differ, which is why they are stocked as a separate SKU rather than treated as interchangeable.
Switching device type or manufacturer changes inhaler technique requirements, dose-counter mechanics and sometimes spacer compatibility, so a substitution at the pharmacy counter carries real technique risk even when the active molecule is identical — a materially different situation from swapping a branded tablet for a generic equivalent.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.